Keyword: Depakine

Sanofi under investigation for manslaughter over epilepsy drug

French pharma giant Sanofi Aventis has been placed under investigation for suspected manslaughter in a judicial probe into the marketing of its epilepsy treatment drug Depakine, which a public watchdog has estimated caused up to 450 babies to be stillborn or contract congenital birth defects in France between 2006 and 2014.

French study says up to 4,100 children harmed by epilepsy drug

Pregnant women treated with valproate, prescribed worldwide for epilepsy and bi-polar disorders and introduced in France in 1967, is believed to have caused malformations, and notably spina bifida, in up to 4,100 children in France, according to a study by the French National Agency for the Safety of Medicines.

France creates 10m-euro compensation fund for epilepsy drug victims

More than 14,000 women in France were prescribed Depakine, the Sanofi drug firm's brand name for valproate, despite the potential risks to foetuses which became known in the early 1980s, and which associations representing victims say may have affected  50,000 people in the country.

Up to 10,000 pregnant French women given epilepsy drug despite risk

Health ministry denies delaying publication of study showing how many women took Sanofi's drug Depakine despite officials knowing dangers.